Platinum‐based chemotherapy plus cetuximab first‐line for Asian patients with recurrent and/or metastatic squamous cell carcinoma of the head and neck: Results of an open‐label, single‐arm, multicenter trial

Zalutumumab plus best supportive care versus best supportive care alone in patients with recurrent or metastatic squamous-cell carcinoma of the head and neck after failure of platinum-based chemotherapy: an open-label, randomised phase 3 trial

The Lancet Oncology ◽

10.1016/s1470-2045(11)70034-1 ◽

2011 ◽

Vol 12 (4) ◽

pp. 333-343 ◽

Cited By ~ 165

Author(s):

Jean-Pascal Machiels ◽

Somasundaram Subramanian ◽

Agnes Ruzsa ◽

Gabor Repassy ◽

Igor Lifirenko ◽

...

Keyword(s):

Squamous Cell Carcinoma ◽

Supportive Care ◽

Cell Carcinoma ◽

Head And Neck ◽

Squamous Cell ◽

Best Supportive Care ◽

Open Label ◽

Phase 3 ◽

Quality of life of patients receiving platinum-based chemotherapy plus cetuximab first line for recurrent and/or metastatic squamous cell carcinoma of the head and neck

Annals of Oncology ◽

10.1093/annonc/mdq077 ◽

2010 ◽

Vol 21 (10) ◽

pp. 1967-1973 ◽

Cited By ~ 69

Author(s):

R. Mesía ◽

F. Rivera ◽

A. Kawecki ◽

S. Rottey ◽

R. Hitt ◽

...

Keyword(s):

Quality Of Life ◽

Squamous Cell Carcinoma ◽

Cell Carcinoma ◽

Head And Neck ◽

Squamous Cell ◽

First Line ◽

Observational study of the cetuximab relative dose intensity (RDI) in the first-line treatment of recurrent and/or metastatic squamous cell carcinoma of the head and neck (R/M SCCHN): Data on the maintenance and every two weeks use (DIRECT study)

Annals of Oncology ◽

10.1093/annonc/mdw376.19 ◽

2016 ◽

Vol 27 ◽

pp. vi334 ◽

Cited By ~ 2

Author(s):

J. Guigay ◽

E. Chamorey ◽

P. Céruse ◽

F. Mornex ◽

M. Degardin ◽

...

Keyword(s):

Squamous Cell Carcinoma ◽

Observational Study ◽

Cell Carcinoma ◽

Head And Neck ◽

Squamous Cell ◽

Dose Intensity ◽

Line Treatment ◽

First Line ◽

First-line versus second-line immunotherapy in recurrent/metastatic squamous cell carcinoma of the head and neck

Annals of Oncology ◽

10.1093/annonc/mdz252.030 ◽

2019 ◽

Vol 30 ◽

pp. v462

Author(s):

C. Even ◽

N. Torossian ◽

T. Ibrahim ◽

N. Martin ◽

L. Mayache Badis ◽

...

Keyword(s):

Squamous Cell Carcinoma ◽

Cell Carcinoma ◽

Head And Neck ◽

Squamous Cell ◽

Second Line ◽

First Line ◽

Phase I dose-finding and pharmacokinetic study of IV vinflunine in combination with methotrexate in patients with recurrent/metastatic squamous cell carcinoma of the head and neck (R/M SCCHN) previously treated with platinum-based chemotherapy.

Journal of Clinical Oncology ◽

10.1200/jco.2015.33.15_suppl.e17049 ◽

2015 ◽

Vol 33 (15_suppl) ◽

pp. e17049-e17049

Author(s):

Audrey Mailliez ◽

Frederic Rolland ◽

Jean Marc Tourani ◽

Cedrik Lafond ◽

Didier Cupissol ◽

...

Keyword(s):

Squamous Cell Carcinoma ◽

Phase I ◽

Cell Carcinoma ◽

Head And Neck ◽

Squamous Cell ◽

Pharmacokinetic Study ◽

Dose Finding ◽

Previously Treated

123MO Monalizumab, cetuximab and durvalumab in first-line treatment of recurrent or metastatic squamous cell carcinoma of the head and neck (R/M SCCHN): A phase II trial

Annals of Oncology ◽

10.1016/j.annonc.2021.10.142 ◽

2021 ◽

Vol 32 ◽

pp. S1432

Author(s):

D.A. Colevas ◽

K. Misiukiewicz ◽

A.T. Pearson ◽

J. Fayette ◽

J.R. Bauman ◽

...

Keyword(s):

Squamous Cell Carcinoma ◽

Cell Carcinoma ◽

Head And Neck ◽

Phase Ii ◽

Squamous Cell ◽

Phase Ii Trial ◽

Line Treatment ◽

First Line ◽

Faculty Opinions recommendation of Phase II study of the combination of cetuximab and weekly paclitaxel in the first-line treatment of patients with recurrent and/or metastatic squamous cell carcinoma of head and neck.

Faculty Opinions – Post-Publication Peer Review of the Biomedical Literature ◽

10.3410/f.13355993.791652823 ◽

2012 ◽

Author(s):

Marco Merlano

Keyword(s):

Squamous Cell Carcinoma ◽

Cell Carcinoma ◽

Head And Neck ◽

Phase Ii ◽

Squamous Cell ◽

Phase Ii Study ◽

Line Treatment ◽

First Line ◽

Faculty Opinions recommendation of Phase II study of the combination of cetuximab and weekly paclitaxel in the first-line treatment of patients with recurrent and/or metastatic squamous cell carcinoma of head and neck.

Faculty Opinions – Post-Publication Peer Review of the Biomedical Literature ◽

10.3410/f.13355993.14726100 ◽

2011 ◽

Author(s):

Jan Vermorken

Keyword(s):

Squamous Cell Carcinoma ◽

Cell Carcinoma ◽

Head And Neck ◽

Phase Ii ◽

Squamous Cell ◽

Phase Ii Study ◽

Line Treatment ◽

First Line ◽

Patritumab with Cetuximab plus Platinum-Containing Therapy in Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck: An Open-Label, Phase Ib Study

Clinical Cancer Research ◽

10.1158/1078-0432.ccr-18-1539 ◽

2018 ◽

Vol 25 (2) ◽

pp. 487-495 ◽

Cited By ~ 4

Author(s):

Magnus T. Dillon ◽

Lorna Grove ◽

Kate L. Newbold ◽

Heather Shaw ◽

Nicholas F. Brown ◽

...

Keyword(s):

Squamous Cell Carcinoma ◽

Cell Carcinoma ◽

Head And Neck ◽

Squamous Cell ◽

Open Label ◽

Phase Ib ◽

Open Label Phase

Clinical outcomes of platinum-based chemotherapy plus cetuximab for recurrent or metastatic squamous cell carcinoma of the head and neck: comparison between platinum-sensitive and platinum-resistant patients

Acta Oto-Laryngologica ◽

10.1080/00016489.2018.1551623 ◽

2019 ◽

Vol 139 (2) ◽

pp. 201-205 ◽

Cited By ~ 2

Author(s):

Hiroki Sato ◽

Kiyoaki Tsukahara ◽

Isaku Okamoto ◽

Yasuaki Katsube ◽

Akira Shimizu ◽

...

Keyword(s):

Squamous Cell Carcinoma ◽

Cell Carcinoma ◽

Head And Neck ◽

Clinical Outcomes ◽

Squamous Cell ◽

Platinum Sensitive ◽

Platinum Resistant ◽